
Olivier Lambotte

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9300614/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Delivering adapted physical activity by videoconference to patients with fatigue under immune checkpoint inhibitors: Lessons learned from the PACTIMe-FEAS feasibility study. Journal of Telemedicine and Telecare, 2023, 29, 716-724.	2.7	7
2	Anti–programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study. European Journal of Cancer, 2022, 160, 134-139.	2.8	10
3	Expansion of Immature Neutrophils During SIV Infection Is Associated With Their Capacity to Modulate T-Cell Function. Frontiers in Immunology, 2022, 13, 781356.	4.8	7
4	The letter responds to comment on: Anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment study. European Journal of Cancer, 2022, 165, 208-209.	2.8	0
5	Reprogramming dysfunctional CD8+ T cells to promote properties associated with natural HIV control. Journal of Clinical Investigation, 2022, 132, .	8.2	15
6	Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma. Joint Bone Spine, 2022, 89, 105390.	1.6	1
7	Detection of SARS-CoV-2 in subcutaneous fat but not visceral fat, and the disruption of fat lymphocyte homeostasis in both fat tissues in the macaque. Communications Biology, 2022, 5, .	4.4	7
8	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Annals of the Rheumatic Diseases, 2021, 80, 36-48.	0.9	153
9	Severe ulcerative gastrointestinal toxicity following ibrutinib therapy: two case studies. Leukemia and Lymphoma, 2021, 62, 984-987.	1.3	2
10	Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Haematologica, 2021, 106, 1414-1422.	3.5	17
11	Severe IgA-mediated autoimmune hemolytic anemia triggered by SARS-CoV-2 infection. Leukemia and Lymphoma, 2021, 62, 2037-2039.	1.3	3
12	Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrinÂalpha4 therapy. European Journal of Cancer, 2021, 145, 230-233.	2.8	6
13	Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis. Immunotherapy, 2021, 13, 465-475.	2.0	9
14	Long-term impact of immunotherapy on quality of life of surviving patients: A multi-dimensional descriptive clinical study. European Journal of Cancer, 2021, 148, 211-214.	2.8	4
15	CXCR3 and CXCR5 are highly expressed in HIVâ€1â€specific CD8 central memory TÂcells from infected patients. European Journal of Immunology, 2021, 51, 2040-2050.	2.9	2
16	Antiretroviral therapy for HIV controllers: Reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort. EClinicalMedicine, 2021, 37, 100963.	7.1	5
17	Immune checkpoint inhibitor–associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. European Journal of Cancer, 2021, 158, 208-216.	2.8	33
18	Leukocyte Immunoglobulin-Like Receptors in Regulating the Immune Response in Infectious Diseases: A Window of Opportunity to Pathogen Persistence and a Sound Target in Therapeutics. Frontiers in Immunology, 2021, 12, 717998.	4.8	29

Olivier Lambotte

#	Article	IF	CITATIONS
19	Elite and viremic HIV-1 controllers in West Africa. Aids, 2021, Publish Ahead of Print, 29-38.	2.2	0
20	Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case–control study. European Journal of Cancer, 2021, 156, 46-59.	2.8	16
21	Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae. Brain Communications, 2021, 3, fcab220.	3.3	16
22	Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities. European Journal of Cancer, 2021, 157, 383-390.	2.8	6
23	The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: AÂprospective study of the French REISAMIC registry. European Journal of Cancer, 2021, 158, 217-224.	2.8	35
24	Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nature Medicine, 2021, 27, 2085-2098.	30.7	146
25	Mass Cytometry Reveals the Immaturity of Circulating Neutrophils during SIV Infection. Journal of Innate Immunity, 2020, 12, 170-181.	3.8	12
26	Systemic lupus erythematosus associated with thymoma: A fifteen-year observational study in France. Autoimmunity Reviews, 2020, 19, 102464.	5.8	5
27	Optimal Maturation of the SIV-Specific CD8+ T Cell Response after Primary Infection Is Associated with Natural Control of SIV: ANRS SIC Study. Cell Reports, 2020, 32, 108174.	6.4	12
28	How to manage patients with corticosteroids in oncology in the era of immunotherapy?. European Journal of Cancer, 2020, 141, 239-251.	2.8	52
29	Infectious complications in patients treated with immune checkpoint inhibitors. European Journal of Cancer, 2020, 141, 137-142.	2.8	24
30	Immune-related adverse events of checkpoint inhibitors. Nature Reviews Disease Primers, 2020, 6, 38.	30.5	684
31	Letter responds to the comment in â€~immune thrombocytopenia of haematological immune-related adverse events in cancer immunotherapy: Most and mighty'. European Journal of Cancer, 2020, 134, 60-61.	2.8	0
32	Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmunity Reviews, 2020, 19, 102586.	5.8	80
33	Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach. Internal and Emergency Medicine, 2020, 15, 587-598.	2.0	16
34	The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. European Journal of Cancer, 2020, 130, 39-50.	2.8	37
35	Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review. British Journal of Haematology, 2020, 189, 985-992.	2.5	27
36	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. Arthritis and Rheumatology, 2019, 71, 2100-2111.	5.6	202

OLIVIER LAMBOTTE

#	Article	IF	CITATIONS
37	HIV controllers: to treat or not to treat? Is that the right question?. Lancet HIV,the, 2019, 6, e878-e884.	4.7	13
38	HIV-1 Envelope Overcomes NLRP3-Mediated Inhibition of F-Actin Polymerization for Viral Entry. Cell Reports, 2019, 28, 3381-3394.e7.	6.4	28
39	Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?. Annals of the Rheumatic Diseases, 2019, 78, 860-862.	0.9	14
40	Cynomolgus macaque IL37 polymorphism and control of SIV infection. Scientific Reports, 2019, 9, 7981.	3.3	3
41	Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncology, 2019, 5, 1310.	7.1	268
42	Inherited Thrombotic Thrombocytopenic Purpura Revealed by Recurrent Strokes in a Male Adult: Case Report and Literature Review. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 1537-1539.	1.6	5
43	Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy. American Journal of Ophthalmology, 2019, 202, 109-117.	3.3	62
44	Cold agglutinin disease as a new immune-related adverse event associated with anti-PD-L1sÂand its treatment with rituximab. European Journal of Cancer, 2019, 110, 21-23.	2.8	10
45	Cardiovascular Events in the French ANRS HIV Controller Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, e32-e34.	2.1	9
46	Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study. , 2019, 7, 337.		75
47	Dynamics in HIVâ€DNA levels over time in HIV controllers. Journal of the International AIDS Society, 2019, 22, e25221.	3.0	21
48	Reply to: "Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?― Journal of Hepatology, 2019, 70, 566-567.	3.7	2
49	Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematology,the, 2019, 6, e48-e57.	4.6	195
50	Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 114-122.	0.8	19
51	Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. Journal of Hepatology, 2018, 68, 1181-1190.	3.7	372
52	Efficacy and safety of rituximab for systemic lupus erythematosusâ€associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. American Journal of Hematology, 2018, 93, 424-429.	4.1	56
53	Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. European Journal of Cancer, 2018, 91, 21-29.	2.8	222
54	Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. European Journal of Cancer, 2018, 96, 91-104.	2.8	94

OLIVIER LAMBOTTE

#	Article	IF	CITATIONS
55	Effect of CRP value on 18F–FDG PET vascular positivity in Takayasu arteritis: a systematic review and per-patient based meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 575-581.	6.4	17
56	Reply to: "Incidence of grade 3–4 liver injury under immune checkpoints inhibitors: A retrospective study― Journal of Hepatology, 2018, 69, 1397-1398.	3.7	2
57	Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?― Journal of Hepatology, 2018, 69, 550-551.	3.7	2
58	A high-resolution mass cytometry analysis reveals a delay of cytokines production after TLR4 or TLR7/8 engagements in HIV-1 infected humans. Cytokine, 2018, 111, 97-105.	3.2	9
59	Reply to: "Mortality due to immunotherapy related hepatitis― Journal of Hepatology, 2018, 69, 978-979.	3.7	0
60	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmunity Reviews, 2017, 16, 650-657.	5.8	32
61	Immune-related bone marrow failure following anti-PD1 therapy. European Journal of Cancer, 2017, 80, 1-4.	2.8	36
62	A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level. Open Forum Infectious Diseases, 2017, 4, ofx064.	0.9	45
63	HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection. EBioMedicine, 2017, 21, 158-169.	6.1	45
64	Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non–small cell lung cancer. European Journal of Cancer, 2017, 85, 155-157.	2.8	6
65	Prevalence of immune-related systemic adverse events inÂpatients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. European Journal of Cancer, 2017, 82, 34-44.	2.8	146
66	Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies. European Journal of Cancer, 2017, 81, 135-137.	2.8	55
67	Detectable HIV-RNA in semen of HIV controllers. PLoS ONE, 2017, 12, e0183376.	2.5	8
68	Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. PLoS ONE, 2017, 12, e0173893.	2.5	30
69	Thymic Epithelial Tumor-Associated Cytopenia: A 10-Year Observational Study in France. Journal of Thoracic Oncology, 2016, 11, 391-399.	1.1	11
70	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature Reviews Clinical Oncology, 2016, 13, 473-486.	27.6	831
71	Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. Blood, 2016, 128, 1625-1630.	1.4	78
72	Risk factors associated with intracranial hemorrhage in adults with immune thrombocytopenia: A study of 27 cases. American Journal of Hematology, 2016, 91, E499-E501.	4.1	20

OLIVIER LAMBOTTE

#	Article	IF	CITATIONS
73	Cancers in elite controllers. Aids, 2016, 30, 1852-1855.	2.2	6
74	Disseminated intravascular coagulation following administration of sunitinib. Molecular and Clinical Oncology, 2016, 5, 121-123.	1.0	1
75	Two cases of immune thrombocytopenia associated with pembrolizumab. European Journal of Cancer, 2016, 54, 172-174.	2.8	52
76	Life-threatening Hughes-Stovin syndrome: The Yin and Yang of anticoagulation therapy. Joint Bone Spine, 2016, 83, 459-460.	1.6	5
77	Public T cell receptors confer high-avidity CD4 responses to HIV controllers. Journal of Clinical Investigation, 2016, 126, 2093-2108.	8.2	63
78	Adipose Tissue Is a Neglected Viral Reservoir and an Inflammatory Site during Chronic HIV and SIV Infection. PLoS Pathogens, 2015, 11, e1005153.	4.7	191
79	Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14658-14663.	7.1	154
80	Immunologic and Virologic Progression in HIV Controllers: The Role of Viral "Blips―and Immune Activation in the ANRS CO21 CODEX Study. PLoS ONE, 2015, 10, e0131922.	2.5	50
81	Blunted Response to Combination Antiretroviral Therapy in HIV Elite Controllers: An International HIV Controller Collaboration. PLoS ONE, 2014, 9, e85516.	2.5	34
82	Successful Outcome of a Corticodependent Henoch-Schönlein Purpura Adult with Rituximab. Case Reports in Medicine, 2014, 2014, 1-4.	0.7	25
83	Efficacy of Recombinant Human Interleukin 7 in a Patient With Severe Lymphopenia-Related Progressive Multifocal Leukoencephalopathy. Open Forum Infectious Diseases, 2014, 1, ofu074.	0.9	29
84	Both HLA-B*57 and Plasma HIV RNA Levels Contribute to the HIV-Specific CD8 ⁺ T Cell Response in HIV Controllers. Journal of Virology, 2014, 88, 176-187.	3.4	39
85	Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome. Arthritis and Rheumatology, 2014, 66, 2613-2620.	5.6	875
86	Autoimmune diseases in HIV-infected patients: 52 cases and literature review. Autoimmunity Reviews, 2014, 13, 850-857.	5.8	101
87	Reduction of death receptor 5 expression and apoptosis of CD4+ T cells from HIV controllers. Clinical Immunology, 2014, 155, 17-26.	3.2	7
88	Elevated IP10 levels are associated with immune activation and low CD4+ T-cell counts in HIV controller patients. Aids, 2014, 28, 467-476.	2.2	85
89	Natural history of HIV-control since seroconversion. Aids, 2013, 27, 2451-2460.	2.2	44
90	High Antibody-Dependent Cellular Cytotoxicity Responses Are Correlated with Strong CD8 T Cell Viral Suppressive Activity but Not with B57 Status in HIV-1 Elite Controllers. PLoS ONE, 2013, 8, e74855.	2.5	76

Olivier Lambotte

#	Article	IF	CITATIONS
91	CD4 Dynamics over a 15 Year-Period among HIV Controllers Enrolled in the ANRS French Observatory. PLoS ONE, 2011, 6, e18726.	2.5	52
92	Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood, 2011, 118, 955-964.	1.4	107
93	Characteristics and Long-Term Outcome of 15 Episodes of Systemic Lupus Erythematosus-Associated Hemophagocytic Syndrome. Medicine (United States), 2006, 85, 169-182.	1.0	112
94	Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Medicine, 2006, 12, 1365-1371.	30.7	3,107
95	Pegylated interferon alpha-2a-associated life-threatening Evans' syndrome in a patient with chronic hepatitis C. Journal of Infection, 2005, 51, e113-e115.	3.3	18
96	HIV Controllers: A Homogeneous Group of HIV-1Infected Patients with Spontaneous Control of Viral Replication. Clinical Infectious Diseases, 2005, 41, 1053-1056.	5.8	355
97	Efficacy of rituximab in refractory polymyositis. Journal of Rheumatology, 2005, 32, 1369-70.	2.0	91